Click to read
the new issue

April 2014

Latest issue

march 2014

Also available from:

download on the app storeget it on google play

“We have to make companies want to do this work”
Incentivising innovation in antibiotic research is now a must

The home stretch
Will short-term financial issues scupper efforts to make homecare a major pillar of UK healthcare?

Multiple sclerosis – the next generation

Are patients really getting what they need?

Just say no
The UK needs to re-energise its clinical trials industry, but sponsors need to know when to walk away from unreasonable costs

Clinical detail
PharmaTimes Magazine talks to this year’s International Clinical Researcher of the Year winners

The R&D machine
Is it time for pharma to stop plugging away at research and switch to open innovation with universities?

Data wars
The bottom line is absolute transparency and no more dirty secrets in the NHS,
says Phil Hammond

Outcomes: a gamechanger for pharma

Patient-recorded outcome measures are likely to become a key part of how healthcare is provided, funded and managed. But is industry ready?

Healthcare Writer Lynne Taylor

The British government’s determination to place health outcomes at the heart of NHS decision-making presents UK-based drugmakers with a unique and potentially huge advantage over their global competitors.

Working in collaboration with the NHS to identify a product’s true value – in other words its value to the patient – has the potential to boost levels of medicines uptake and could also lead to products arriving earlier to market, both in the UK and overseas, a PharmaTimes business meeting was told recently. Leading these potentially game-changing opportunities is the NHS patient-recorded outcome measures programme, which began in 2009.

Innovative drugmakers have included PROMs in their clinical trials for many years, and the data have also long been used in observational studies and population health surveys. “We have decades of experience using these instruments and pharma is way ahead of the game. The fact they are now being measured in healthcare systems changes everything,” Professor Nancy Devlin, research director at the Office of Health Economics told the meeting. Indeed, PROMs are likely to become a key part of how all healthcare is provided, funded and managed, The King’s Fund healthcare policy think-tank has forecast.

So what exactly are PROMs and why should this matter to pharma? You can find out by reading the full article online here

See what's coming up in the March issue [PDF]

Visions 2014 supplement


Creating a balance between
reimbursement and innovation

Real-world data
How to plan early

NHS reform
What more does pharma need to do?

We asked you what the big developments in 2014 will be?

Change is key to opportunity
What to adapt for

Salesforce effectiveness
Future-proofing the sales team

Myeloma research
An example of a new R&D model

Visions in a nutshell

The complete Visions 2014 supplement PDF is available to download


Subscription is free to qualifying UK subscribers

To read articles in full and features in the magazine, why not subscribe

Reprints available.

Average circulation Jan - Dec 2013: 23,178


Head-to-Head Video


Website Search

Search News Search Magazine


Elert Signup!